Vigil Neuroscience, Inc. (VIGL)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Vigil Neuroscience, Inc. (VIGL)
Company Performance

Current Price

as of Oct 18, 2024

$3.96

P/E Ratio

N/A

Market Cap

$157M

Description

Vigil Neuroscience, Inc. engages in the provision of biotechnology research services. Its focus is improving the lives of patients, caregivers, and families affected by neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. The company was founded on June 22, 2020 and is headquartered in Watertown, MA.

Metrics

Overview

  • HQWatertown, MA
  • SectorHealth Technology
  • IndustryBiotechnology
  • TickerVIGL
  • Price$3.96-0.75%

Trading Information

  • Market Cap$157.00M
  • Float50.82%
  • Average Daily Volume (1m)124,165
  • Average Daily Volume (3m)148,880
  • EPS-$2.12

Company

  • RevenueN/A
  • Rev Growth (1yr)N/A
  • Net Income-$21.23M
  • Gross MarginN/A
  • EBITDA MarginN/A
  • EBITDA-$22.37M
  • EV$88.99M
  • EV/RevenueN/A
  • P/EN/A
  • P/SN/A
  • P/B1.75
Documents
SEC Filings
8-K (2024-09-17)
8-K (2024-08-13)
8-K (2024-07-24)
8-K (2024-07-18)
8-K (2024-06-27)
8-K (2024-06-06)
8-K (2024-05-07)
8-K (2024-03-26)
8-K (2024-01-11)
8-K (2023-11-16)
8-K (2023-11-07)
8-K (2023-10-12)
8-K (2023-09-13)
8-K (2023-09-08)
8-K (2023-08-08)
8-K (2023-06-08)
8-K (2023-05-10)
8-K (2023-05-09)
8-K (2023-03-30)
8-K (2023-03-21)
8-K (2023-03-10)
8-K (2023-02-10)
8-K (2023-01-09)
10-Q (2024-08-13)
10-Q (2024-05-07)
10-Q (2023-11-07)
10-Q (2023-08-08)
10-Q (2023-05-10)
10-K (2024-03-26)
10-K (2023-03-21)
Factset
Factset Business Description
Factset Street Account
Vigil Neuroscience reports Q3 EPS ($0.53) vs FactSet ($0.57) [8 est, ($0.69)-(0.45)] ($6.85, 0.00) (2023-11-07T12:25:54Z)
Vigil Neuroscience reports interim data from phase 2 IGNITE trial evaluating Iluzanebart (VGL101) as treatment for ALSP and from ongoing natural history study ILLUMINATE; call at 16:30ET ($6.60, 0.00) (2023-11-16T21:20:29Z)
Vigil Neuroscience provides update on its small molecule TREM2 agonist, VG-3927 - 8-K ($5.50, 0.00) (2023-10-12T20:19:14Z)
Vigil Neuroscience initiated market outperform at JMP Securities ($6.58, 0.00) (2023-10-18T05:10:11Z)
Vigil Neuroscience announces first participant dosed in phase 1 trial in healthy volunteers evaluating VG-3927 ($6.17, 0.00) (2023-10-17T11:07:32Z)